HSR waiting period expires for Bristol-Myers Squibb’s tender offer for Inhibitex

By CPI | February 3, 2012

Bristol-Myers Squibb has announced that the Hart-Scott-Rodino waiting period has expired for its cash tender offer to purchase all outstanding shares of common stock of Inhibitex. Inhibitex is a drug maker that develops drugs for treating hepatitis C. The tender offer will expire at midnight EST on February 10.